Currently Viewing:
The American Journal of Managed Care February 2013
Are Benefits From Diabetes Self-Management Education Sustained?
JoAnn Sperl-Hillen, MD; Sarah Beaton, PhD; Omar Fernandes, MPH; Ann Von Worley, RN, BSHS, CCRP; Gabriela Vazquez-Benitez, PhD, MSc; Ann Hanson, BS; Jodi Lavin-Tompkins, RN, CNP, CDE, BC-ADM; William Parsons, MS; Kenneth Adams, PhD; and C. Victor Spain, DVM, PhD
Currently Reading
Impact of Oral Nutritional Supplementation on Hospital Outcomes
Tomas J. Philipson, PhD; Julia Thornton Snider, PhD; Darius N. Lakdawalla, PhD; Benoit Stryckman, MA; and Dana P. Goldman, PhD
Oral Nutritional Supplementation
Gordon L. Jensen, MD, PhD
Medical Homes Require More Than an EMR and Aligned Incentives
Samantha L. Solimeo, PhD, MPH; Michael Hein, MD, MS; Monica Paez, BA; Sarah Ono, PhD; Michelle Lampman, MA; and Greg L. Stewart, PhD
Do Electronic Medical Records Improve Diabetes Quality in Physician Practices?
Jeffrey S. McCullough, PhD; Jon Christianson, PhD; and Borwornsom Leerapan, MD, PhD
Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy
Suja S. Rajan, MHA, MS, PhD; William R. Carpenter, MHA, PhD; Sally C. Stearns, PhD; and Gary H. Lyman, MD, MPH
The Cost of Implementing Inpatient Bar Code Medication Administration
Julie Ann Sakowski, PhD; and Alana Ketchel, MPP, MPH
Spending and Mortality in US Acute Care Hospitals
John A. Romley, PhD; Anupam B. Jena, MD, PhD; June F. O'Leary, PhD; and Dana P. Goldman, PhD
Cost-Effectiveness of Medicare Drug Plans in Schizophrenia and Bipolar Disorder
Kenneth J. Smith, MD, MS; Seo Hyon Baik, PhD; Charles F. Reynolds III, MD; Bruce L. Rollman, MD, MPH; and Yuting Zhang, PhD
Introducing Forensic Health Services Research
Laurence F. McMahon Jr, MD, MPH; and Vineet Chopra, MD, MSc
Guidance for Structuring Team-Based Incentives in Healthcare
Daniel M. Blumenthal, MD, MBA; Zirui Song, PhD; Anupam B. Jena, MD, PhD; and Timothy G. Ferris, MD, MPH

Impact of Oral Nutritional Supplementation on Hospital Outcomes

Tomas J. Philipson, PhD; Julia Thornton Snider, PhD; Darius N. Lakdawalla, PhD; Benoit Stryckman, MA; and Dana P. Goldman, PhD
Instrumental variables regression analysis indicated that inpatient oral nutritional supplement use decreased length of stay, episode cost, and 30-day readmission probability.
Objectives: To assess the effect of inpatient oral nutritional supplement (ONS) use on length of stay, episode cost, and 30-day readmission probability.

Study Design: Eleven-year retrospective study (2000 to 2010).

Methods: Analyses were conducted using the Premier Perspectives Database, which contained information on 44.0 million adult inpatient episodes. Using a matched sample of ONS and non-ONS episodes for any inpatient diagnosis, instrumental variables regression analysis was performed to quantify the effect of ONS use on length of stay, episode cost, and probability of approximate 30-day readmission. For the readmission outcome, the matched sample was restricted to episodes where the patient was known to be at risk of readmission. The fraction of a hospital’s episodes in a given quarter involving ONS was used as an instrumental variable.

Results: Within the database, 1.6% of 44.0 million adult inpatient episodes involved ONS use. Based on a matched sample of 1.2 million episodes, ONS patients had a shorter length of stay by 2.3 days (95% confidence interval [CI] – 2.42 to –2.16), from 10.9 to 8.6 days (21.0% decline), and decreased episode cost of $4734 (95% CI – $4754 to – $4714), from $21,950 to $17,216 (21.6% decline). Restricting the matched sample to the 862,960 episodes where patients were readmitted at some point, ONS patients had a reduced probability of early readmission (within 30 days) of 2.3 percentage points (95% CI – 0.027 to – 0.019), from 34.3% to 32.0% (6.7% decline).

Conclusions: Use of ONS decreases length of stay, episode cost, and 30-day readmission risk in the inpatient population.

(Am J Manag Care. 2013;19(2):121-128)
Malnutrition is a serious but underappreciated problem among hospitalized patients. There is relatively little evidence evaluating the large-scale effectiveness of therapeutic interventions against malnutrition. We conducted an instrumental variables analysis to determine the effect of oral nutritional supplement use in the inpatient setting.

  • Use of oral nutrition supplements decreased length of stay, episode cost, and probability of 30-day readmission.

  •  By increasing oral nutrition supplement use, hospitals can improve hospitalization outcomes and decrease healthcare spending.
Malnutrition is a serious and underappreciated problem among hospitalized patients. Malnourished patients face heightened risks of poor outcomes, including increased length of stay (LOS),1-3 healthcare costs,1-4 complication rates,2,4-7 readmission rates,8,9 and mortality.2,10-12

Estimates of malnutrition prevalence in the inpatient population range from 8% to 62%, depending on the location and the specific patient population considered.13-17 Groups at highest risk include elderly as well as oncology and gastroenterology patients.16 Despite evidence documenting the deleterious effects of malnutrition in the inpatient setting, studies suggest it is a common problem that often goes unrecognized and undertreated.15,18

A growing body of evidence suggests that oral nutrition supplements (ONS), which deliver both macronutrients and micronutrients for special medical purposes in addition to normal food, might improve outcomes among hospitalized patients. A variety of benefits have been found for ONS use, including reduced LOS,3 inpatient episode cost,3,19 complication rates,19,20 depressive symptoms,21 and readmission rates,22,23 and improved lean body mass recovery.24 However, previous studies suffer from limitations, including modest sample sizes, narrowly selected patient populations, and in observational studies, possible selection bias. Consequently, questions remain regarding the robustness and generalizability of existing findings and the size of gains and healthcare costs associated with ONS use in hospitalized patients.

This retrospective data analysis was conducted to assess the association and causal impacts of ONS on health outcomes for hospitalized patients, focusing on 3 key outcomes: LOS, episode cost, and probability of 30-day readmission.


Setting, Subjects, and Data Sources

This analysis was conducted using the Premier Perspectives Database. This database contains diagnostic and billing information on 44.0 million adult inpatient episodes at 460 sites during the years 2000 to 2010. Premier estimates that these data cover 20% of all US inpatient episodes. The sample was restricted to adults 18 years or older and excluded terminal episodes and all episodes involving tube feeding, leaving only oral feeding for examination. All monetary figures were reported in 2010 dollars and inflation-adjusted based on the Bureau of Labor Statistics medical Consumer Price Index ( cpi/#tables).


The study’s 3 key outcome variables were LOS, episode cost, and probability of 30-day readmission. Length of stay was defined as the number of days of direct patient care (minimum 1 day) from admission to discharge. Episode cost was defined as the actual costs to treat the patient during the hospitalization. Thirty-day readmission probability was defined as a return hospitalization for any diagnosis. For patient confidentiality purposes, the Premier database only contains the month and year of an inpatient episode. Therefore, the 30-day readmission window was calculated by identifying admissions later the same month or during the following month. Given that there are no International Classification of Diseases, Ninth Revision or Current Procedural Terminology codes that identify ONS use, ONS was defined as a “complete nutritional supplement, oral,” as indicated by the Premier data, and coded as a binary variable, indicating any ONS used during the inpatient episode.

Statistical Analysis

Naïve ordinary least squares (OLS) regression analyses were performed on the full matched sample. Analyses controlled for a variety of patient, episode, and provider characteristics. Demographic covariates included age, age squared, insurance type, marital status, race, and sex. Comorbidity covariates included all components of the Charlson Comorbidity Index.25,26 Health history covariates included whether the patient had been admitted to any Premier network hospital in the previous 6 months, and whether the patient was admitted from the emergency department, by physician referral, or by inter-facility transfer. Hospital- specific covariates included number of beds, urban location, whether the site was a teaching hospital, and region (Northeast, Midwest, West, or South as defined by US Census data). Time trends were controlled for using year and quarter dummies.

Treatment is assigned randomly in clinical trials to avoid confounding; however, there is potential for selection bias in observational research from unobserved factors that may influence study outcomes.27,28 Because it is likely to be administered to individuals who are less healthy, ONS use could be spuriously associated with increased LOS. Additionally, only certain patient health-related risk factors were directly observable with available data. Therefore, further methods were used to remove these sources of potential selection bias: propensity score matching and instrumental variables analysis.

Propensity Score Matching. To diminish the potential for confounding due to differences in observed personal characteristics and to identify nutritionally at-risk patients, propensity score matching29 was used to match ONS episodes to similar non-ONS episodes. The probability of receiving ONS was estimated using a logistic regression of ONS based on the covariates noted above. After removing all episodes involving children (<18 years) and tube feeding, each ONS episode was matched to its nearest non-ONS episode neighbor.

Instrumental Variables Analysis. Instrumental variable analysis was used to specifically address potential bias due to nonrandomized treatment selection, which could not be addressed with propensity matching alone. Instrumental variables can remove the effect of selection bias and identify the causal effect of a treatment on outcomes.30-32 Using this method requires an instrument that correlates with the treatment of interest but does not affect the outcome, except through its influence on the likelihood of receiving treatment.

For this analysis, the selected instrument was the fraction of episodes involving any ONS use in a given hospital in a given quarter. By looking at changes in ONS use based on a hospital’s inclination to prescribe it, rather than underlying patient characteristics, the unbiased identification of the effect of ONS was made feasible. Since instrumental variable properties are best understood in linear settings,33 this instrument was applied to linear models of the 3 outcomes. Several tests of the instrument’s validity were performed.

To control further for unobserved patient heterogeneity, the model included fixed effects for groups based on how long patient data remained observable prior to loss to follow-up. These fixed-effects “follow-up” groups were no patient follow- up data; 1 day through 1 year of follow-up; 1 to 2 years of follow-up; 2 to 3 years of follow-up; and more than 3 years of follow-up. Because life expectancy cannot generally be observed in the Premier database (except when individuals die in a Premier network hospital), follow-up duration served as a proxy for underlying health status. Observed follow-up using hospital-based data may be a preferable measure of overall patient frailty, because the diagnostic codes present in a single episode (vs multiple follow-up episodes) are unlikely to reflect the full range of patient comorbidities.

Additional Modeling of Readmissions. For the readmission outcome, the matched sample was restricted to episodes where the patient was known to be at risk of readmission following discharge. If patients did not die following hospitalization, it could be assumed ONS had 2 potential benefits: it prevented readmissions by making people healthy, or it delayed readmissions among those eventually readmitted. Because the Premier data did not distinguish between patients not readmitted due to recovery and those not readmitted due to death, the current study could only measure the effect of delayed readmission (by calculating the change in 30-day readmission probability among patients eventually readmitted). This approach also provided a conservative estimate of the total impact of ONS on readmission.

Return on Investment Calculations. Next, estimates for the effect of ONS on LOS, episode cost, and readmission probability were used to calculate a return on investment (ROI) for ONS use, using the following formula:

ROI = savings generated through ONS use – amount spent on ONS

amount spent on ONS

The above formula yields the “episode cost” ROI of ONS use through reduced episode cost. Savings generated from ONS use were defined as the average reduction in episode cost due to ONS use. The amount spent on ONS was the average episode cost of ONS use. For readmission ROI, the average episode cost among the readmitted population was multiplied by the reduction in the probability of readmission to calculate the savings generated through ONS use. The amount spent on ONS was defined as for the episode cost ROI.

Computation. Analyses were performed using Stata version 11 (StataCorp LP, College Station, Texas). A 2-sided P value of .05 or less was considered statistically significant. A detailed summary of additional testing and sensitivity analyses conducted to validate study results can be found in the eAppendix (available at


From 46.1 million inpatient episodes and 810,589 episodes involving ONS use, we excluded 306,528 tube-feeding episodes, 1,798,907 involving patients under age 18 years, 112 with incomplete data, and 19,817 terminal episodes to obtain a sample of 44.0 million episodes and 724,027 ONS episodes. The overall rate of ONS use in adult inpatient episodes was 1.6%. Each adult ONS episode was matched to an adult non-ONS episode, to obtain a matched sample of 1,160,088 episodes.

Mean characteristics of ONS episodes, all non-ONS episodes, and matched non-ONS episodes are reported in Table 1. Compared with general non-ONS inpatient episodes, individuals receiving ONS were older (age 68.4 vs 56.7 years) and less healthy on various dimensions; and 42.2% of ONS episodes were preceded by an admission in the prior 6 months, compared with only 25.6% for non-ONS episodes. The average LOS for an ONS episode was 12.5 days compared with 4.8 days for non-ONS episodes.

Table 2 shows the characteristics of matched ONS sample subgroups by follow-up group. Patient ONS use was highly correlated with other health markers, including prior admission history, LOS, episode cost, and Charlson Comorbidity Index score.

Length of Stay

Ordinary least squares regression analysis performed on the full matched sample showed that ONS use was associated with a 2.9-day (95% confidence interval [CI] 2.8-3.0 days), or 34.7%, increase in LOS, from 8.3 to 11.2 days. However, when instrumental variables regression analysis was used to account for selection bias, ONS lowered LOS by 2.3 days (95% CI -2.4 to -2.2 days), or 21.0%, from 10.9 to 8.6 days (Table 3, columns 1 and 2).

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up